Condition: Colorectal Cancer · Colorectal Adenocarcinoma · Colorectal Cancer Stage II · Sponsor: City of Hope Medical Center
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
This description comes directly from the study's public registry record.
Ajay Goel, PhD · 6262183452 · AJGOEL@COH.ORG
Always discuss trial participation with your own doctor first.
| City of Hope Medical Center | Monrovia, California, United States | Recruiting |
| Second Affiliated Hospital of Dalian Medical University | Dalian, China | Recruiting |
| Barcelona University | Barcelona, Spain | Recruiting |
| La Paz University Hospital | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06314958